Printer Friendly

Amgen's sBLA for XGEVA (denosumab) to expand the currently approved indication for the prevention of skeletal-related events in patients with bone metastases from solid tumors, has been approved to include multiple myeloma.

Amgen's sBLA for XGEVA (denosumab) to expand the currently approved indication for the prevention of skeletal-related events in patients with bone metastases from solid tumors, has been approved to include multiple myeloma. The approval is based on data from the pivotal Phase III '482 study, the largest international multiple myeloma clinical trial ever conducted, which enrolled 1,718 patients.

"Up to 40 percent of patients remain untreated for the prevention of bone complications, and the percentage is highest among patients with renal impairment at the time of diagnosis," said Noopur Raje, M.D., director, Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston. "Denosumab, which is not cleared through the kidneys, offers multiple myeloma patients bone protection with a convenient subcutaneous administration, providing patients with a novel treatment option."

XGEVA is a fully human monoclonal antibody that binds to and neutralizes RANK ligand (RANKL)--a protein essential for the formation, function and survival of osteoclasts, which break down bone--thereby inhibiting osteoclast-mediated bone destruction. It is currently the number one prescribed bone-targeting agent in the U.S. for the prevention of skeletal-related events in patients with bone metastases from solid tumors. Additional regulatory applications for XGEVA for the prevention of skeletal-related events in patients with multiple myeloma are underway and have been submitted to health authorities worldwide.

COPYRIGHT 2018 Rodman Publishing
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Filings
Publication:Contract Pharma
Date:Jan 1, 2018
Words:217
Previous Article:Novartis' sBLA for Kymriah (tisagen-lecleucel) suspension for intravenous infusion.
Next Article:Morphotek's IND for MORAb-202.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters